Atlas Trials

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

RecordFirmDate
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study (NCT04536558)Sun Yat-sen University2020-10-01

Track Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy automatically

Every clearance here is in the API, with alerts when new ones post.